On Monday 14th November, the ANZUP Cancer Trials Group and COSA’s Urologic Oncology group convened a Clinical Professional day as a satellite to the 38th COSA Annual Scientific Meeting in Perth. The day focused on case-based discussion on genito-urinary cancer, and was well subscribed with over 60 registrants from all the relevant medical and allied health specialties in attendance. Amgen sponsorship allowed the use of audience responder panels, which allowed for plenty of interactive input.

A particularly pleasing aspect of the day was the ANZUP PoCoG and OZPOS joint session: “Below the belt” - what are we missing in caring for GU patients? focusing on psychosocial aspects of testicular and prostate cancer. Chaired by Dr Jane Turner, psychiatrist, the session started with informative presentations by Mr. Ben Smith and Dr Addie Wooten. A panel discussion followed involving A/Prof Mark Frydenberg (urologist), Ms Kim Hobbs (social worker), A/Prof Nigel Spry (radiation oncologist), Dr Siobhan Ng (medical oncologist), Dr Isabel White (nurse practitioner) and Dr Wootten (psychologist) on relevant cases.

The prostate cancer session “That old chestnut” was chaired by A/Prof Nigel Spry, radiation oncologist, with panelists Mr. Paul Sved (urologist), Dr Siobhan Ng (medical oncologist), Dr Emma Hamilton (endocrinologist), A/Prof Mark Frydenberg (urologist), Dr Serena Sia (radiation oncologist), and Ms Kath Schubach (nurse practitioner). Topics addressed through case-based discussion included early detection, decision-making for early prostate cancer, adjuvant & salvage therapy for recurrent or residual disease and systemic therapy for M0 & asymptomatic M1 disease.

After lunch, the program was split between urothelial cancer of the bladder and renal cancer. The first half was chaired by A/Prof Mike Wallace, urologist, with a panel including Dr Seth Lerner (urologist), Dr Liz Hovey (medical oncologist), Dr Ronnie Cohen (pathologist), A/Prof Nigel Spry (radiation oncologist) and Ms Fran Lee (nurse practitioner). Topics covered early diagnosis & haematuria assessment, NMIBC – treatment decision-making, MIBC – reconstructive options after cystectomy and systemic therapy – what’s on the horizon.

The Renal Cancer session: “The nephron-sparing imperative” was chaired by Dr Simon Troon, medical oncologist, and a panel including Prof Tim Eisen (medical oncologist), Dr Ronnie Cohen (pathologist), A/Prof Mike Wallace (urologist), A/Prof Mark Frydenberg (urologist), A/Prof Nigel Spry (radiation oncologist), Mr. Gregory Bock (nurse), and Dr James Anderson (Radiologist). Topics included the incidental small renal mass – diagnostic dilemma, surgical alternatives for localised disease, management of local recurrence and systemic therapy – neoadjuvant use and management of toxicity.

The final session on germ cell tumours, “Options for playing hard ball” was chaired by A/Prof Guy Toner, medical oncologist. The panel included Mr. Shane La Bianca (urologist), Dr Serena Sia (radiation oncologist), Ms Afaf Girgis (psycho-oncology) and Mr. Justin Vivian (urologist). Topics covered included decision-making for Stage I disease, treatment modality of choice for nodal mass, post-chemotherapy recurrence and fertility and sexual function.

The day was made possible by funding from COSA, and a lot of hard work from A/Prof Ian Davis in putting the cases together. Session chairs & panelists are to be commended for
their input in preparing the cases, for their valuable time on the day and most of all for informative and stimulating discussion. Feedback from those attending was “very good” to “excellent”; with the main criticism being the lack of time to adequately cover the full breadth of the information. We are hopeful that we can run similar workshops in the future, and this year’s experience and feedback with help to build on and improve the program content for future meetings.

ANZUP acknowledges and thanks COSA for the CPD grant. ANZUP also acknowledges the funding received from the Australian Government through Cancer Australia.

We thank Novartis, Pfizer, Amgen and Pierre Fabre for their generous support for our Clinical Professional Day.